J. Molner (MOLNR) H1 2026 earnings summary

Executive summary

• June 1 acquisition of an FDA-approved U.S. product portfolio expanded marketed products from 4 to 14 and added hospital and specialty pharmacy access; H1 includes one month of acquired sales.

• Revenue rose to €1.965m from €551k; reported net profit was €1.442m, with €3.694m of non-recurring, non-cash negative goodwill income.

Financial highlights

• H1 revenue €1.965m, up 256% YoY; generic-drug sales €1.555m, up 868%, while services revenue increased 5% to €410k.

• Operating profit €1.559m versus a €1.508m loss; net profit €1.442m versus a €1.412m loss in H1 2025.

• Raw materials, goods and services costs rose to €2.134m from €359k; other direct costs were €412k, including €206k of inventory write-offs.

Outlook and guidance

• Rights to acquired products not currently marketed are expected to support launches in H1 2027; the development pipeline continued across formulation, stability and regulatory review.

• Strategy targets niche, established medicines facing supply gaps, with moderate-volume production and flexible CMO partnerships to support supply continuity.